Denali Therapeutics Inc’s recent filing unveils that its Chief Medical Officer Ho Carole unloaded Company’s shares for reported $0.25 million on Jan 06 ’25. In the deal valued at $20.22 per share,12,255 shares were sold. As a result of this transaction, Ho Carole now holds 178,580 shares worth roughly $3.41 million.
Then, Ho Carole sold 2,907 shares, generating $60,495 in total proceeds. Upon selling the shares at $20.81, the Chief Medical Officer now owns 175,673 shares.
Before that, Schuth Alexander O. sold 12,255 shares. Denali Therapeutics Inc shares valued at $247,796 were divested by the COFO and Secretary at a price of $20.22 per share. As a result of the transaction, Schuth Alexander O. now holds 247,215 shares, worth roughly $4.72 million.
Robert W. Baird initiated its Denali Therapeutics Inc [DNLI] rating to an Outperform in a research note published on January 07, 2025; the price target was $31. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in early January with a ‘”an Outperform”‘ rating. Stifel also remained covering DNLI and has increased its forecast on December 16, 2024 with a “Buy” recommendation from previously “Hold” rating.
Price Performance Review of DNLI
On Friday, Denali Therapeutics Inc [NASDAQ:DNLI] saw its stock fall -10.12% to $19.10. Over the last five days, the stock has lost -8.35%. Denali Therapeutics Inc shares have fallen nearly -6.28% since the year began. Nevertheless, the stocks have fallen -3.24% over the past one year. While a 52-week high of $33.33 was reached on 01/08/25, a 52-week low of $14.56 was recorded on 01/10/25. SMA at 50 days reached $24.36, while 200 days put it at $23.09.
Levels Of Support And Resistance For DNLI Stock
The 24-hour chart illustrates a support level at 18.25, which if violated will result in even more drops to 17.39. On the upside, there is a resistance level at 20.38. A further resistance level may holdings at 21.65. The Relative Strength Index (RSI) on the 14-day chart is 33.54, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.25, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.85%. Stochastics %K at 40.99% indicates the stock is a holding.
How much short interest is there in Denali Therapeutics Inc?
A steep rise in short interest was recorded in Denali Therapeutics Inc stocks on 2024-12-13, growing by 0.37 million shares to a total of 7.46 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 7.1 million shares. There was a rise of 4.9%, which implies that there is a positive sentiment for the stock.
